Merck announced that the FDA has accepted for review the Biologics License Application (BLA) for MK-8237, Merck’s house dust mite...
ALK has obtained European approval for its HDM-SLIT (house dust mite sublingual allergy immunotherapy tablet) against allergic rhinitis and allergic...
ALK has announced that its house dust mite sublingual allergy immunotherapy (SLIT) tablet Acarizax has had its approval in 12...
ODACTRA is an allergen extract indicated as immunotherapy for the treatment of house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive in vitro testing for IgE antibodies to Dermatophagoides farinae or Dermatophagoides pteronyssinus house dust mites or by positive skin testing to licensed house dust mite allergen extracts.
ALK has announced that The Journal of the American Medical Association (JAMA) has published results from a Phase III clinical...
ALK has presented trial results on Mitizax (sublingual allergy immunotherapy tablet or SLIT-tablet) for House Dust Mite (HDM) respiratory Allergic...
ALK Abello announced positive top-line results from the pivotal Phase III MITRA trial conducted with the allergy immunotherapy tablet against...
Merck has submitted a Biologics License Application (BLA) to the FDA for its house dust mite (HDM) sublingual allergy immunotherapy...
Circassia Pharmaceuticals plc announces top-line results from its investigational house dust mite allergy immunotherapy phase IIb field study. In the...